ReviewJournal of personalized medicine2021
Psychosis in Women: Time for Personalized Treatment.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis.Schizophrenia bulletin · 2026Guideline
- Sense of agency and its disturbances: A systematic review targeting the intentional binding effect in neuropsychiatric disorders.Psychiatry and clinical neurosciences · 2024Pooled it
- Sex differences in neurocognitive response to metacognitive training in first-episode psychosis: Implications for personalized interventions.Archives of women's mental health · 2026Trial
- Demographic and clinical profiles of drug-induced psychosis: age, gender, and social context in a German cohort.European archives of psychiatry and clinical neuroscience · 2026Article
- Women's Care in First-Episode Psychosis: Clinicians' Perspectives on Service Provision.Early intervention in psychiatry · 2026Article
- Exploring the relationship between dissociative experiences and recovery in psychosis: cross-sectional study.BJPsych bulletin · 2026Article
- The Global Burden of Schizophrenia: Findings from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study.Schizophrenia bulletin open · 2026Article
- Unmasking the cycle: Premenstrual and menstrual exacerbation of psychiatric disorders and impact on female mental health.World journal of psychiatry · 2025Review
- Lifetime prevalence of psychotic experience, and its associated factors among Senegalese women: a cross-sectional study.BMC psychiatry · 2025Article
- Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials.Biomedicines · 2025Review
- Women with Schizophrenia: Beyond Psychosis.Community mental health journal · 2025Article
- Comparison of male and female non-refugee immigrants with psychosis: clinical, sociodemographic, and migration-related differences and impact on stress.Archives of women's mental health · 2024Article
- Keep in mind sex differences when prescribing psychotropic drugs.World journal of psychiatry · 2024Article
- Sex differences in schizophrenia-spectrum diagnoses: results from a 30-year health record registry.Archives of women's mental health · 2024Article
- Novel Advancements in COVID-19 and Neuroscience.Journal of personalized medicine · 2024Article
- Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study.Brain sciences · 2024Article
- Treatment Analysis of Very Early and Early Onset Psychosis in the Youth Inpatient Setting.HCA healthcare journal of medicine · 2024Article
- The Translational Future of Stress Neurobiology and Psychosis Vulnerability: A Review of the Evidence.Current neuropharmacology · 2024Review
- What Came First, Mania or Depression? Polarity at Onset in Bipolar I and II: Temperament and Clinical Course.Brain sciences · 2023Article
- Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.BMC psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection and prompt treatment of psychosis is of the utmost importance. The great variability in clinical onset, illness course, and response to pharmacological and psychosocial treatment is in great part gender-related. Our aim has been to review narratively the literature focusing on gender related differences in the psychoses, i.e., schizophrenia spectrum disorders. We searched the PubMed/Medline, Scopus, Embase, and ScienceDirect databases on 31 July 2021, focusing on recent research regarding sex differences in early psychosis. Although women, compared to men, tend to have better overall functioning at psychotic symptom onset, they often present with more mood symptoms, may undergo misdiagnosis and delay in treatment and are at a higher risk for antipsychotic drug-induced metabolic and endocrine-induced side effects. Furthermore, women with schizophrenia spectrum disorders have more than double the odds of having physical comorbidities than men. Tailored treatment plans delivered by healthcare services should consider gender differences in patients with a diagnosis of psychosis, with a particular attention to early phases of disease in the context of the staging model of psychosis onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.